The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Annual report to the nation on the status of cancer, part 1: National cancer statistics
Open accessAbstract
Background: The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate to provide annual updates on cancer occurrence and trends in the United States. Methods: Data on new cancer diagnoses during 2001–2018 were obtained from the North American Association of Central Cancer Registries’ Cancer in North America Incidence file, which is comprised of data from Centers for Disease Control and Prevention‐funded and National Cancer Institute‐funded, population‐based cancer registry programs. Data on cancer deaths during 2001–2019 were obtained from the National Center for Health Statistics' National Vital Statistics System. Five‐year average incidence and death rates along with trends for all cancers combined and for the leading cancer types are reported by sex, racial/ethnic group, and age. Results: Overall cancer incidence rates were 497 per 100,000 among males (ranging from 306 among Asian/Pacific Islander males to 544 among Black males) and 431 per 100,000 among females (ranging from 309 among Asian/Pacific Islander females to 473 among American Indian/Alaska Native females) during 2014–2018. The trend during the corresponding period was stable among males and increased 0.2% on average per year among females, with differing trends by sex, racial/ethnic group, and cancer type. Among males, incidence rates increased for three cancers (including pancreas and kidney), were stable for seven cancers (including prostate), and decreased for eight (including lung and larynx) of the 18 most common cancers considered in this analysis. Among females, incidence rates increased for seven cancers (including melanoma, liver, and breast), were stable for four cancers (including uterus), and decreased for seven (including thyroid and ovary) of the 18 most common cancers. Overall cancer death rates decreased by 2.3% per year among males and by 1.9% per year among females during 2015–2019, with the sex‐specific declining trend reflected in every major racial/ethnic group. During 2015–2019, death rates decreased for 11 of the 19 most common cancers among males and for 14 of the 20 most common cancers among females, with the steepest declines (>4% per year) reported for lung cancer and melanoma. Five‐year survival for adenocarcinoma and neuroendocrine pancreatic cancer improved between 2001 and 2018; however, overall incidence (2001–2018) and mortality (2001–2019) continued to increase for this site. Among children (younger than 15 years), recent trends were stable for incidence and decreased for mortality; and among, adolescents and young adults (aged 15–39 years), recent trends increased for incidence and declined for mortality. Conclusions: Cancer death rates continued to decline overall, for children, and for adolescents and young adults, and treatment advances have led to accelerated declines in death rates for several sites, such as lung and melanoma. The increases in incidence rates for several common cancers in part reflect changes in risk factors, screening test use, and diagnostic practice. Racial/ethnic differences exist in cancer incidence and mortality, highlighting the need to understand and address inequities. Population‐based incidence and mortality data inform prevention, early detection, and treatment efforts to help reduce the cancer burden in the United States.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Pearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30150-5 · Cited by 307
RetractedPearson-Stuttard, J., Zhou, B., Kontis, V., Bentham, J., Gunter, M. J., & Ezzati, M. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30366-2 · Cited by 265
RetractedSiegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Self-citationBody Fatness and Cancer — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1606602 · Cited by 3,596
WHO Classification: Tumours of the Haematopoietic and Lymphoid Tissues (2008)
(2015) · Postgraduate Haematology · doi:10.1002/9781118853771.ch51 · Cited by 3,290
Breast cancer statistics, 2019
DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21583 · Cited by 3,114
Self-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
(2020) · PubMed · Cited by 2,642
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Timmerman, R. (2010) · JAMA · doi:10.1001/jama.2010.261 · Cited by 2,532
Cited by
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Self-citationPancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
High-throughput PRIME-editing screens identify functional DNA variants in the human genome
Ren, X., Yang, H., Nierenberg, J. L., Sun, Y., Chen, J., Beaman, C., Pham, T., Nobuhara, M., Takagi, M. A., Narayan, V., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.11.021 · Cited by 70
Cahoon, E. K., Mandal, S., Pfeiffer, R. M., Wheeler, D. C., Sargen, M. R., Alexander, B. H., Kitahara, C. M., Linet, M. S., & Mai, J. Z. (2024) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djae186 · Cited by 10
Metadata
- Authors
- Cronin, K. A., Scott, S., Firth, A. U., Sung, H., Henley, S. J., Sherman, R. L., Siegel, R. L., Anderson, R. N., Kohler, B. A., Benard, V. B., Negoita, S., Wiggins, C., Cance, W. G., & Jemal, A.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2022-10-27
- Volume
- 128
- Issue
- 24
- Pages
- 4251-4284
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W4307381352
- Cited by
- 557
- References
- 82
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Annual report to the nation on the status of cancer, part 1: National cancer statistics. https://app.cochat.ai/papers/10.1002/cncr.34479
- The paper
- Cronin, K. A., Scott, S., Firth, A. U., Sung, H., Henley, S. J., Sherman, R. L., Siegel, R. L., Anderson, R. N., Kohler, B. A., Benard, V. B., Negoita, S., Wiggins, C., Cance, W. G., & Jemal, A. (2022). Annual report to the nation on the status of cancer, part 1: National cancer statistics. Cancer. https://doi.org/10.1002/cncr.34479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.